Literature DB >> 34283023

Pregnant Women's Attitudes Toward and Experiences With a Tablet Intervention to Promote Safety Behaviors in a Randomized Controlled Trial: Qualitative Study.

Bente Walter1, Hege Indreboe1, Mirjam Lukasse1,2, Lena Henriksen1, Lisa Garnweidner-Holme1.   

Abstract

BACKGROUND: Intimate partner violence (IPV) is recognized as a global health problem. Women with low education and limited resources are more vulnerable, as are immigrant women. There is a lack of evidence on how health care professionals should communicate about and intervene against IPV during pregnancy. Earlier research has shown that when women manage digital questionnaires, they are more likely to disclose IPV. However, little is known about how women experience eHealth interventions with safety behaviors to prevent IPV.
OBJECTIVE: The aim of this study was to explore pregnant women's attitudes toward and experiences with a tablet intervention to promote safety behaviors in a randomized controlled trial (RCT) in antenatal care.
METHODS: Individual semistructured interviews were conducted with 10 women who participated in the Safe Pregnancy Study. The Safe Pregnancy Study was a randomized controlled trial (RCT) using a tablet intervention containing IPV questions and a film to promote safety behaviors. Six women from the intervention group and four women from the control group were recruited. The content was available in Norwegian, Somali, and Urdu. Five of the women participating in the interviews spoke Norwegian at home and five spoke another language. The majority of the women who did not speak Norwegian at home perceived themselves as relatively well integrated. The interviews were conducted at different maternal and child health centers (MCHCs) in Norway between March 2020 and June 2020. The analysis was guided by thematic analysis.
RESULTS: Women who participated in the tablet intervention appreciated being asked questions about IPV on a tablet. However, it was important to supplement the tablet intervention with face-to-face communication with a midwife. The MCHC was regarded as a suitable place to answer questions and watch a film about safety behaviors. Women suggested making the tablet intervention available in other settings where women meet health care professionals. Some women expressed uncertainty about their anonymity regarding their answers in the questionnaire. We found no real differences between ethnic Norwegian and immigrant women's attitudes toward and experiences with the tablet intervention.
CONCLUSIONS: Questions about IPV and a film about safety behaviors on a tablet, as a supplement to face-to-face communication, might initiate and facilitate communication about IPV in antenatal care. Uncertainty regarding anonymity has to be addressed when questions about IPV are being asked on a tablet. TRIAL REGISTRATION: ClinicalTrials.gov NCT03397277; https://clinicaltrials.gov/ct2/show/NCT03397277. ©Bente Walter, Hege Indreboe, Mirjam Lukasse, Lena Henriksen, Lisa Garnweidner-Holme. Originally published in JMIR Formative Research (https://formative.jmir.org), 20.07.2021.

Entities:  

Keywords:  antenatal care, safety behaviors; eHealth; intimate partner violence; pregnancy; tablet intervention

Year:  2021        PMID: 34283023     DOI: 10.2196/28680

Source DB:  PubMed          Journal:  JMIR Form Res        ISSN: 2561-326X


  2 in total

1.  Antenatal depression and the association of intimate partner violence among a culturally diverse population in southeastern Norway: A cross-sectional study.

Authors:  Thea Cathrine Melby; Nina Benedicte Sørensen; Lena Henriksen; Mirjam Lukasse; Eva Marie E Flaathen
Journal:  Eur J Midwifery       Date:  2022-07-18

2.  Safe Pregnancy intervention for intimate partner violence: a randomised controlled trial in Norway among culturally diverse pregnant women.

Authors:  Eva Marie Engebakken Flaathen; Lena Henriksen; Milada Cvancarova Småstuen; Berit Schei; Angela Taft; Josef Noll; Lisa Garnweidner-Holme; Mirjam Lukasse
Journal:  BMC Pregnancy Childbirth       Date:  2022-02-21       Impact factor: 3.007

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.